Denali outlines 2023 milestones: four late-stage programs, IND for DNL126, OTV expansion

Denali Therapeutics Inc.

Four programs expected in late-stage: DNL310 (MPS II), BIIB122 (Parkinson's), SAR443820 (ALS), DNL343 ALS Phase 2/3
DNL126 (ETV:SGSH) for MPS IIIA: IND submission H1 2023, Phase 1/2 recruitment H2 2023
Oligonucleotide TV platform: five ASO targets selected; two OTV candidates advancing toward clinic
DNL343 (eIF2B activator) ALS: final Phase 1b data mid-2023; Phase 2/3 in HEALEY Platform Trial mid-2023

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.